Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SyntheMed's REPEL-CV gets Russian go-ahead

This article was originally published in Clinica

Executive Summary

The Ministry of Health of the Russian Federation has approved REPEL-CV, SyntheMed's bioresorbable adhesion barrier film, for all patients undergoing open heart surgery. The device is designed to be placed over the surface of the heart after surgery, to reduce the formation of scars, and hence prevent the heart becoming attached to the sternum or other tissues. It will be marketed in Russia by Cardiomedics, a distributor of cardiac surgery products. REPEL-CV received US FDA premarket approval in March for paediatric cardiac surgery patients (see Clinica No 1336, p 27). Iselin, New Jersey-based SyntheMed has also CE marked the film for sale in Europe for all cardiac surgery patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel